San Diego, California-based MediVas LLC, a drug and biologic delivery system developer, has selected Taiwan as the site of its Asian branch.
Taiwan beat out rivals South Korea, Singapore and China for the center.
Kenneth Carpenter, MediVas president and chief executive officer, said yesterday that Taiwan was probably the most dynamic economy in Asia and its way of doing business was very similar to that of the US.
"But, most importantly, the government has a strong commitment in making the biotech and pharmaceutical industry a trillion [dollar] industry," he said, referring to the decision to pick Taiwan.
The close bond between the government and the private biotechnology sector was shown last week when the state-owned National Development Fund announced it would invest US$20 million in TaiMed Biologics Co (
Unlike most biotech and pharmaceutical firms, MediVas' business focuses mainly on changing the way pharmaceuticals are delivered.
Its technology platform uses protein-like polymeric biomaterials to make drug and biological delivery more effective than before.
But what makes the new investment in Taiwan more interesting is that MediVas Asia's facility here will focus on the development of so-called "super-generic" drugs, MediVas Asia president Huang Hui-hui (
The firm defines super-generics as drugs whose original patents have expired and which are repatented by MediVas Asia.
"This repatenting is a result of modifying the delivery route of the drug and that will lead to several advantages," Huang Hui-hui said on the sidelines of yesterday's launch ceremony.
These potential advantages include longer duration of drug effectiveness, less undesirable side effects and changes in the method of administration, she said.
"For example, you might stop taking a drug by intravenous injection and start to use subcutaneous injections instead, or you may be allowed to use oral administration instead of subcutaneous injections used in the past," she said.
MediVas Asia had originally talked to local pharmaceuticals, whose business is primarily focused on production of cheap generic drugs, about joint development of super-generics.
But local firms showed little interest in the idea because they did not want invest in a market which is both small and fragmented, said Huang Bor-fuei (黃博輝), a director at the Development Center for Biotechnology (生物技術開發中心) in charge of industry promotion and marketing.
What makes the situation more worrisome is the eroding regional competitiveness of the nation's biotch sector in recent years, he said.
"People in Asia are now talking about emerging markets like China and India ... and Taiwan has drop-ped off the radar screen in biotechnology in this region," he said.
Minister Without Portfolio Lin Feng-ching (
He praised the introduction of super generics by MediVas Asia as a way to upgrade local industry's technological level.
Huang Hui-hui said MediVas Asia was deciding to set up its own research and development center here and would establish its own manufacturing facilities for super generics production by the end of this year.
MediVas Asia is based at Taipei's Nangang Software Park (南港軟體園區) and has an initial capitalization of NT$5 million (US$151,300).
The company plans to increase its capitalization by seeking government financing as well as new partners, including venture capital firms and local pharmaceuticals, Huang Hui-hui said.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained